Intractable & Rare Diseases Research is a pioneering journal dedicated to advancing the understanding and treatment of rare and intractable diseases. Published by INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENT in Japan, this esteemed journal serves as a critical platform for researchers, clinicians, and healthcare professionals to share groundbreaking findings and developments in the field. With its established Scopus ranking of #238 out of 636 in the General Medicine category, placing it in the 62nd percentile, and its classification in the Q3 quartile for 2023, it is recognized as a significant contributor to the literature on rare diseases. Operating without an open-access model, the journal ensures high-quality content cultivated through rigorous peer-review processes. Through its scope spanning from 2012 to 2024, the journal aspires to bridge gaps in knowledge and foster collaboration among interdisciplinary researchers, ultimately aiming to improve patient outcomes and enhance public health concerning these challenging conditions.

Molecular Medicine Reports, an esteemed academic journal published by Spandidos Publications Ltd, serves as a vital platform for the dissemination of cutting-edge research in the field of molecular medicine. Established in 2008, this journal has rapidly ascended in prominence, currently positioned within the Q2 and Q3 quartiles across various critical categories including Biochemistry, Cancer Research, and Genetics, reflecting its significant impact and scholarly contributions. With an impressive Scopus ranking in multiple disciplines, including an 87th place in Oncology, it is recognized for publishing rigorous, peer-reviewed articles that bridge the gap between laboratory research and clinical applications. The journal’s commitment to advancing knowledge in molecular medicine is evident through its focus on innovative therapeutic approaches, genetic research, and oncological studies, catering to a diverse readership of researchers, professionals, and students in the biomedical field. Though not an open-access publication, it provides invaluable insights and fosters collaboration in the scientific community from its base in Athens, Greece.

Biomedical Research and Therapy is a pioneering journal published by BIOMEDPRESS, dedicated to the field of biomedical sciences. With its ISSN 2198-4093, this journal aims to disseminate high-quality research and innovative therapies that advance knowledge in biomedical research. Although it operates on a non-open access model, it provides crucial insights into various topics such as drug discovery, disease mechanisms, regenerative medicine, and clinical applications. The journal's rigorous peer-review process ensures the publication of critical findings and methodologies, making it a vital resource for researchers, practitioners, and students interested in the constantly evolving landscape of biomedical research. With converged years from 2020 to 2024 and an emerging reputation in its field, Biomedical Research and Therapy is positioned to contribute significantly to the global scientific community, enriching the discourse around therapeutic advancements and biomedical innovations.

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

Biomedica is a distinguished journal published by the Instituto Nacional de Salud in Colombia, dedicated to advancing knowledge within the fields of biochemistry, genetics, molecular biology, and general medicine. Since its inception in 1981, this Open Access journal has embodied a commitment to disseminating high-quality research, ensuring free and universal access to its published works. With an impressive Scopus Ranking—273rd out of 636 in Medicine and 148th out of 221 in Biochemistry, Genetics and Molecular Biology—Biomedica holds a Q3 category in both disciplines as of 2023, reflecting its growing impact and relevance in the scientific community. The journal welcomes contributions that further our understanding and lead to advancements in healthcare and biological sciences, serving as a critical resource for researchers, professionals, and students alike. The journal operates within a continuous publication model from 2001 to 2024, enriching the academic landscape with contemporary findings and fostering collaboration within the biomedical field.

Bulletin of Russian State Medical University, published by the esteemed PIROGOV RUSSIAN NATL RESEARCH MEDICAL UNIV, serves as a crucial platform for advancing the field of medicine, particularly in the context of Russian healthcare advancements. With an ISSN of 2500-1094 and an E-ISSN of 2542-1204, this journal has emerged as a valuable resource for researchers, professionals, and students alike, enriching the academic landscape since its inception. Although categorized in the Q4 quartile for Medicine (miscellaneous) and currently ranked #385 out of 636 in the Scopus database, its ongoing commitment to disseminating vital research and clinical studies positions it as a respected, though evolving, contributor to the global medical community. Operating without an open-access model, it ensures the dissemination of quality-controlled scientific information while maintaining professional integrity. Spanning the intersecting domains of healthcare practices and medical science, the journal strives to provide insights and promote discussions that address contemporary challenges in the field, making it an essential read for anyone looking to stay at the forefront of medical research and practices in Russia and beyond.

Byulleten Sibirskoy Meditsiny, published by the Siberian State Medical University, is a pivotal open-access journal in the field of Molecular Medicine, with its current edition indexed under the ISSN 1682-0363. Since its transition to open access in 2013, the journal aims to disseminate high-quality research and advancements in biomedical sciences, particularly focusing on molecular mechanisms and therapeutic interventions. Despite its relatively recent recognition in Molecular Medicine, where it ranks in the 6th percentile, the journal is dedicated to fostering knowledge exchange and collaboration among researchers, professionals, and students alike. With a modest impact factor and quarterly publication, Byulleten Sibirskoy Meditsiny is positioned to serve as a valuable resource for those engaged in the intricate realms of molecular biology, biochemistry, and general medicine, contributing to the broader scientific discourse in the Russian Federation and beyond.

EBioMedicine is an esteemed open-access journal published by ELSEVIER, dedicated to advancing the fields of biochemistry, genetics, and molecular biology, as well as medicine. Since its inception in 2014, EBioMedicine has established itself as a prominent platform for disseminating high-quality research, evidenced by its impressive rankings in Scopus, where it holds a Q1 category in both Biochemistry, Genetics and Molecular Biology and Medicine for 2023. With an exceptional impact factor that places it in the top percentiles (97th in Medicine and 93rd in Biochemistry), the journal is recognized for its rigorous peer-review process and its commitment to fostering scientific collaboration. Open access since its launch, EBioMedicine ensures that groundbreaking research is readily available to researchers, professionals, and students worldwide, enhancing knowledge dissemination and driving innovation in these crucial fields. For those seeking to stay at the forefront of biomedical research, EBioMedicine is an invaluable resource.

Archives of Clinical Infectious Diseases is a peer-reviewed journal dedicated to advancing knowledge in the field of infectious diseases, published by BRIEFLAND in Iran. With a broad scope, it covers various aspects of cardiology, critical care, immunology, microbiology, public health, and toxicology, affirming its relevance in today's health landscape. Despite the lack of open access options, the journal maintains a strong reputation, reflected in its Q3 ranking in multiple categories within the 2023 category quartiles. The journal aims to provide a platform for researchers and practitioners to disseminate critical findings that can impact clinical practices and public health policies. Its commitment to rigorous peer review ensures that only high-quality research is published, thereby serving as an essential resource for professionals, students, and public health advocates. For those engaged in the ever-evolving world of infectious diseases, Archives of Clinical Infectious Diseases stands as a vital contribution to the medical literature.

Biomarkers in Medicine is a prominent academic journal dedicated to advancing the field of medical biochemistry and drug discovery. Published by Future Medicine Ltd in the United Kingdom, this journal aims to provide a platform for researchers, clinicians, and biotechnology professionals to share their findings on the critical role of biomarkers in diagnosis, treatment, and prognosis of various diseases. With a focus on high-quality, peer-reviewed research, Biomarkers in Medicine supports the dissemination of innovative approaches and therapeutic developments across its converged publication years from 2008 to 2024. Rated in the Q3 category for biochemistry (medical), clinical biochemistry, and drug discovery, it occupies a significant place in its field, attracting contributions that push the boundaries of knowledge and application. Although it does not offer open access, the journal remains committed to excellence and rigor in the representation of ground-breaking studies, making it an essential resource for scholars and professionals eager to stay at the forefront of biomarker research.